
The FDA grants accelerated approval to subcutaneous amivantamab for head and neck cancer, extending the IV-to-subcutaneous shift in biologics formulation.
This study attempts to determine the combination of excipients found in commercial ASA products that would be suitable for use in an aqueous enteric film­coating process.
about 25 years ago
Evaluation of Gelatins for Cross-Linking Potentialabout 25 years ago
Fast-Melting Tablets: Developments and Technologiesabout 25 years ago
Compendium of Pharmaceutical Excipients for Vaginal Formulations





